TX-FLUENCE
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the successful continuation of its partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization that focuses on molecular farming and medicinal plants.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201728532/en/
Fluence and Innexo's partnership tests the effects of eliminating the vegetation phase for cannabis cultivation. (Photo: Business Wire)
Fluence and Innexo’s research partnership is focused on assessing the viability of cultivating cannabis without a standard vegetative phase, a practice generally associated with lower energy use that passes savings directly to growers in Europe and around the globe. Preliminary data from Fluence and Innexo demonstrates the potential of the “no-veg” growing method to help growers save money while improving quality and consistency. The Fluence and Innexo teams intend to collaborate on a full-scale research project to validate these initial results.
“At Innexo, we use our deep knowledge of cannabis cultivars and best propagation practices to help growers create the most efficient cultivation strategies possible,” said Dominique van Gruisen, managing director of Innexo. “We naturally gravitate toward partners like Fluence who can match our expertise and commitment to investing in innovative and impactful cannabis research.”
Most commercial cannabis cultivators use a vegetative phase to ensure proper plant growth to support flower weight and to gain a full and dense canopy. This phase can last anywhere between seven days and four weeks, requiring a significant investment of time, electrical energy and resources. Initial findings from Fluence and Innexo demonstrate the potential of this method to maintain crop quality and yield while creating up to 55% savings on annual electrical costs directly associated with lighting.
When the plants would typically enter the vegetative phase, they were instead transplanted to the flowering room, where they immediately received their maximum light intensity. In this system, cannabis crops reach their final height—between 70 and 120 cm—around 28 days after transplant. Eliminating two weeks of vegetative phase represents up to 252 hours of direct electricity savings per light per crop cycle. Additional savings are realized through lower HVAC costs and generally more efficient cultivation cycles. Initial research indicates that “no-veg” growing is most effective with plant densities between eight and 10 plants per m2. Thus far, research has tested the viability of “no-veg” growing across six cannabis cultivars, 10 different nutrient lines and a wide range of light intensities.
“Proper lighting—which must include a strong combination of advanced fixtures and lighting strategy—plays a critical role in creating a more efficient and profitable methodology for cannabis cultivation,” said Dr. David Hawley, principal scientist at Fluence. “This research demonstrates the value of examining and investing in a research-backed lighting strategy from day one. Our goal is to explore, validate and demonstrate the effectiveness of diverse cultivation strategies to ensure every grower can apply data-driven methodologies to their facilities in collaboration with Fluence.”
Fluence and Innexo’s research uncovered potential savings for growers who pursue growing without a vegetative phase, including an average of both 40% lower electrical costs and up to 40% lower labor costs per crop cycle. Because of the fast-paced growth of the plants, researchers found there was less time for pests and diseases to develop, leading to a healthier end product. In addition, this method could reduce waste by eliminating C-Grade flower, which allows for more crop cycles per year and increases overall predictability for growers.
“At Fluence, we create value for growers throughout the world by investing in research that will expand the horizons of traditional cultivation,” said Sebastian Olschowski, research project manager for EMEA at Fluence. "As plant lighting specialists, we are proud to be part of this project to shape the future of cannabis research and transfer valuable knowledge to our customers and partners.”
Fluence and Innexo’s research collaboration, which began in 2022, has expanded to include collaborations in three of Innexo’s Acceleration Platform for Innovation (API) programs. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation.
For more information on Fluence and its ongoing global research initiatives, visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.
About Innexo BV
Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit www.innexo.nl.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201728532/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 202513.10.2025 01:31:00 CEST | Press release
Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring its potential to enhance therapeutic options for patients with metastatic prostate cancer The upcoming presentation at ESMO will feature updated safety and efficacy results from all seven Phase 1b treatment cohorts AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC). This will be t
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 202513.10.2025 00:05:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. “We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs.” Details on INCA33890 and INCB161734 oral presentations at ESMO include: INCA33890 (PD-1/TGFβR
Day Two of the 11th World FZO Congress Highlights the Role of Digitization and Sustainability in Shaping the Future of Free Zones11.10.2025 16:52:00 CEST | Press release
The World Free Zones Organization’s 11th annual World Congress continued its agenda today with a focus on the role of digitization and sustainability in the future of free zones and the mechanisms for enhancing their position as strategic trade gateways. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251011933300/en/ Dr Al Zarooni and President of CIRD launching the global institute (Photo: AETOSWire) The day’s sessions featured a series of sessions addressing critical themes such as the digitization of trade corridors, the impact of the OECD Global Minimum Tax, and the role of free zones as regional trade gateways. Sustainability took centre stage with sessions focusing on the transition to net-zero through renewable energy, circular economy models, and green financing frameworks. Speakers underscored that decarbonization is not only a climate imperative but also a competitive advantage for the next generation of free zones
IonQ to Participate in ComoLake2025, Advancing Quantum Collaboration in Italy10.10.2025 22:05:00 CEST | Press release
IonQ CEO to discuss how quantum accelerates innovation and economic growth at Italy’s leading tech and policy forum IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in the ComoLake2025 Digital Innovation Forum, one of Italy’s most prominent technology events focused on digital transformation, infrastructure, and innovation policy. At ComoLake2025, taking place October 14–17 at the Villa Erba International Exhibition and Congress Center in Cernobbio, Niccolò de Masi, Chairman and CEO at IonQ, will deliver a special address, offering strategic insights into how quantum computing is reshaping infrastructure, industry, and Europe’s digital leadership. Marco Pistoia, Senior Vice President of Industry Relations at IonQ, will participate in the round table “Pan-European Quantum Industry Forum - Dialogue between Industry, Politics, and Research for Europe's Quantum Leadership” focused on strengthening Europe’s position in the global quantum landscape. Organized b
IonQ to Participate in GITEX Dubai 2025, Showcasing Advancements in Quantum Infrastructure and Security10.10.2025 22:05:00 CEST | Press release
Executives at IonQ and ID Quantique to address the future of quantum-safe infrastructure and cloud platforms at one of the world’s largest tech events IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in GITEX Global 2025, one of the world’s largest and most influential technology exhibitions, taking place October 13-17 at the Dubai World Trade Centre. IonQ executives and partners will highlight advancements in quantum computing, secure infrastructure, and commercial applications that are accelerating enterprise adoption of quantum technologies. Rima Alameddine, Chief Revenue Officer at IonQ, will speak on the panel “Cracking the Quantum Code: How to Build a Profitable Business in the Quantum Economy,” on October 14, in Hall 10, AI stage. This session will convene global quantum leaders to discuss the path from breakthrough science to viable commercial success, including how to unlock investment, scale quantum solutions, and deliver near-term value across
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom